Hepatitis B Hepatitis B  Chronically infected individuals with persistently elevated serum alanine aminotransferase, a marker of liver damage, and HBV DNA levels are candidates for therapy.  Treatment lasts from six months to a year, depending on medication and genotype.  Treatment duration when medication is taken by mouth, however, is more variable and usually longer than one year. Although none of the available medications can clear the infection, they can stop the virus from replicating, thus minimizing liver damage.  As of 2018, there are eight medications licensed for the treatment of hepatitis B infection in the United States.  These include antiviral medications lamivudine, adefovir, tenofovir disoproxil, tenofovir alafenamide, telbivudine, and entecavir, and the two immune system modulators interferon alpha-2a and PEGylated interferon alpha-2a.  In 2015 the World Health Organization recommended tenofovir or entecavir as first-line agents Hepatitis B Hepatitis B